Repligen moved further into cell-processing services by announcing an acquisition of BioLife Solutions valued around $1.5 billion, aiming to broaden its presence across cell therapy manufacturing workflows. The deal underscores continued consolidation among CDMO and cell-processing providers. Alongside the BioLife transaction, the same update highlighted other bioprocessing and contract manufacturing moves, including expansion plans tied to service capacity and global footprint. For biotech sponsors, these transactions can translate into expanded end-to-end support for cell therapy production—though customer mapping and integration timelines will be key to watch as the market digests consolidation.